Nicole LaBrosse - 16 Feb 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
SVP, CHIEF FINANCIAL OFFICER
Signature
/s/ James R. Oehler, Attorney-in-Fact
Issuer symbol
HALO
Transactions as of
16 Feb 2023
Net transactions value
-$124,382
Form type
4
Filing time
21 Feb 2023, 18:00:58 UTC
Previous filing
17 Feb 2023
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $0 +5,094 +78% $0.000000 11,591 16 Feb 2023 Direct
transaction HALO Common Stock Sale $124,382 -2,525 -22% $49.26 9,066 16 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Restricted Stock Units Options Exercise $0 -5,094 -25% $0.000000 15,279 16 Feb 2023 Common Stock 5,094 $0.000000 Direct F2
transaction HALO Option to Purchase Common Stock Award $0 +61,061 $0.000000 61,061 16 Feb 2023 Common Stock 61,061 $49.26 Direct F3
transaction HALO Restricted Stock Units Award $0 +21,316 $0.000000 21,316 16 Feb 2023 Common Stock 21,316 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported disposition of 2,525 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2 This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
F3 This option vests one-fourth on such date and then 1/48th monthly thereafter.
F4 This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.